Seth Klarman's Baupost Group Fully Exits Vaxcyte Ahead of Pivotal VAX-31 Phase 3 Readout
核心洞察
Seth Klarman's Baupost Group (搜索) eliminated its entire 800,000-share stake in Vaxcyte (PCVX) during Q2 2026, disclosed in a 13F filed August 13, 2026.
Vaxcyte's lead candidate VAX-31, a 31-valent pneumococcal conjugate vaccine, faces a binary catalyst with topline Phase 3 OPUS-1 data expected in Q4 2026.
The exit was corroborated by Assenagon Asset Management's 91.3% position reduction, though Bank of New York Mellon increased its stake by 5.6%.
Seth Klarman's Baupost Group (搜索) has fully exited its position in Vaxcyte (NASDAQ: PCVX), a clinical-stage vaccine developer, eliminating its entire 800,000-share stake during the second quarter of 2026. The divestment, disclosed in a 13F filing dated August 13, 2026, represents a change in position value of -$46,488,000 and comes just weeks before the company's lead vaccine candidate faces a pivotal clinical readout.
The move was not isolated. During the same second-quarter window, Assenagon Asset Management S.A. (搜索) dramatically reduced its PCVX position by 91.3%, cutting its holding from over a million shares to just 101,433 shares. These significant reductions from two prominent institutional players signal a notable shift in sentiment among sophisticated allocators. However, the institutional picture is not uniformly bearish: Bank of New York Mellon Corp. (搜索) increased its PCVX holdings by 5.6% as of a July 28, 2026 filing, accumulating an additional 474,526 shares.
A Binary Catalyst on a Defined Timeline
Vaxcyte is a clinical-stage biotechnology company with no approved products and, consequently, zero product revenue. Its value hinges on VAX-31, a 31-valent pneumococcal conjugate vaccine candidate currently undergoing Phase 3 trials. The most immediate and significant binary catalyst is the expected release of topline safety, tolerability, and immunogenicity data from the OPUS-1 adult study in Q4 2026, which is being run head-to-head against competing pneumococcal vaccines. Further topline results from the OPUS-2 and OPUS-3 trials are anticipated in the first half of 2027.
Beyond its adult studies, VAX-31 is also being evaluated in an infant Phase 2 dose-finding study, with topline data expected at a near-term but unspecified date. A second program, VAX-A1, targeting Group A Streptococcus (搜索), is in much earlier development, having dosed its first participant in a Phase 1 study on June 2, 2026.
Financial Profile and Cash Burn
Vaxcyte reported a Q2 2026 net loss of $284.30 million on $267.85 million in research and development spending, and it relied on a $601.80 million equity offering in February 2026 to maintain its runway. The company's cash position stands at $2.51 billion. The trailing twelve-month free cash flow shows a substantial burn of -$8.32 per share, with TTM operating cash flow declining a further -44.8% year-over-year, and net income declining -65.2% year-over-year on a TTM basis.
Despite these losses, Vaxcyte demonstrates a strong near-term liquidity position, with a current ratio of 5.72 and a cash ratio of 0.675, indicating ample working capital to cover short-term liabilities. The P/E ratio stands at -7.60x and EV/EBITDA at -7.91x, figures that are standard for a pre-revenue biotech investing heavily in clinical trials.
Insider Selling and Analyst Divergence
A noteworthy cluster of insider selling occurred within a nine-day window in late July and early August 2026, involving four distinct senior officers with no corresponding insider purchases reported. CEO Grant Pickering sold 18,198 shares for approximately $1.01 million on July 27; Chief Technical Operations Officer Harpreet S. Dhaliwal sold 17,000 shares for about $935,000 on August 5; President & CFO Andrew Guggenhime sold 10,000 shares for roughly $539,000 on August 3; and COO Jim Wassil sold 2,250 shares for approximately $121,000 on August 3. The aggregate value of these sales exceeds $2.6 million.
Analyst sentiment presents a notable discrepancy depending on data source and timing. The most current analyst data available (as of August 16, 2026) indicates a highly bullish consensus: all 11 covering analysts rate PCVX as a "Buy," with a median price target of $89.00, implying upside of approximately 53.3% relative to the current price of $58.07. However, an earlier consensus report from August 4, 2026, drawing from nine analysts, showed a "Hold" consensus comprising six "Buy" ratings, one "Hold," and two "Sell" ratings.
Implications for the Catalyst Calendar
The market's assessment of PCVX hinges on the upcoming Q4 2026 VAX-31 trial results. A positive outcome would likely validate the bullish analyst sentiment and the confidence of remaining institutional holders, potentially propelling the stock toward the $89.00 analyst target. Conversely, negative outcomes would exacerbate concerns highlighted by Klarman's exit and recent insider selling, potentially leading to a significant price re-evaluation.
For investors, the stock represents a high-stakes bet on clinical success, balanced by strong internal liquidity but challenged by recent smart money and insider exits at current valuation levels. The catalyst calendar runs through OPUS-1 in Q4 2026 and OPUS-2 and OPUS-3 in H1 2027, and the true test of Vaxcyte's trajectory lies in the data expected later this year.